Obstructive sleep apnea (OSA) is a common disease, affecting 2–7% of population, but many of them are still undiagnosed. Nukute has developed a novel and cost effective technology to pre-screen and assist in treatment of OSA patie...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
RTC-2015-3446-1
Nuevos paradigmas no hospitalarios para la simplificación de...
50K€
Cerrado
SOMNIO
Replacing sleep labs The first clinical grade home based di...
4M€
Cerrado
A3BL
Airofit Better Breathing Better Life
71K€
Cerrado
DPI2017-84280-R
SIMPLIFICACION DEL DIAGNOSTICO DE LA APNEA DEL SUEÑO INFANTI...
188K€
Cerrado
PID2021-126455OB-I00
ECOSISTEMA DE SALUD INTELIGENTE PARA EL MANEJO DE ENFERMEDAD...
176K€
Cerrado
Información proyecto PREDESA
Duración del proyecto: 6 meses
Fecha Inicio: 2016-02-22
Fecha Fin: 2016-08-31
Líder del proyecto
NUKUTE OY
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Obstructive sleep apnea (OSA) is a common disease, affecting 2–7% of population, but many of them are still undiagnosed. Nukute has developed a novel and cost effective technology to pre-screen and assist in treatment of OSA patients. Innovation utilizes noise (respiratory rate and profile) and acceleration of chest and diaphragm (respiratory motion) first time as biomarkers of OSA. In the pre-screening device a stereo microphone measures the ambient and respiratory sounds, and an accelerometer measures the motion of neck muscles. In addition to these components, the diagnostic device has also two more accelerators and a blood oxygen level measurement. In both cases, the data is wirelessly sent to the mobile phone application. If the device includes the treatment feature, an electrical stimulation prompts the user to adjust sleeping position for increased airflow, when apnea occurs. The first prototype of the device achieved a proof of the concept in the preclinical tests in the beginning of 2015 and the results were very good. The main benefits of this system compared to existing pre-screening and diagnostic devices are easiness to use, cheapness (70-90% cheaper than competitors), accuracy and comfort wireless design. The device has two main product lines: OSA diagnostic and treatment assistance device for professional use and OSA pre-screening and treatment assistance device for consumers. In a first stage, the target market of diagnostic device is Finnish hospitals and that of pre-screening device is consumers in the US. The device has potential to generate big societal savings in Europe and worldwide by offering cost-effective and easy way to pre-screen OSA. The main activities of this project are: creation of patent family in the US, creation of quality management system and application of CE marking, and preparation of US market entry combined with business plan updating.